On Acceleron's most advanced product sotatercept (ACE - 011) and ACE - 031. Sotatercept, activin receptor type 2A antagonist in the second phase of testing for the treatment of renal anemia and chemotherapy-induced anemia, is in collaboration with Celgene Corporation. ACE - 031, a myostatin (GDF - 8) in the second phase of testing for the treatment of Duchenne muscular dystrophy (DMD) inhibitor, is in collaboration adenosine triphosphate with Shire PLC (LSE: SHP; NASDAQ stock code: SHPGY).
Other options sent a message on that matter (3) Check the history of (a) the relevant research information (7) on that matter (2) I can not open I can not open
POWERED BY
No comments:
Post a Comment